Beijing Chunlizhengda Medical Instruments Co., Ltd. (HKG:1858)
Hong Kong · Delayed Price · Currency is HKD 12.35
-0.22 (-1.75%)
Mar 4, 2026, 4:08 PM HKT
HKG:1858 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,044 | 805.22 | 1,207 | 1,199 | 1,107 |
Other Revenue | - | 0.64 | 1.04 | 2.58 | 0.91 |
| 1,044 | 805.86 | 1,209 | 1,202 | 1,108 | |
Revenue Growth (YoY) | 29.52% | -33.32% | 0.58% | 8.43% | 18.18% |
Cost of Revenue | - | 289.37 | 353.34 | 301.53 | 264.11 |
Gross Profit | 1,044 | 516.49 | 855.18 | 900.08 | 844.03 |
Selling, General & Admin | - | 285.54 | 427.61 | 430.31 | 372.73 |
Research & Development | - | 133.1 | 157.45 | 162.34 | 104.84 |
Other Operating Expenses | 742.01 | 1.62 | 4.41 | 13.33 | 9.2 |
Operating Expenses | 742.01 | 424.53 | 593.88 | 618.73 | 499.58 |
Operating Income | 301.75 | 91.96 | 261.3 | 281.35 | 344.44 |
Interest Expense | - | -0.04 | -0.09 | -0.05 | - |
Interest & Investment Income | - | 27.29 | 26.47 | 23.6 | 10.76 |
Currency Exchange Gain (Loss) | - | 1.78 | 2.48 | 3.57 | -0.86 |
Other Non Operating Income (Expenses) | -0.53 | -0.9 | -0.18 | -4.27 | -4.22 |
EBT Excluding Unusual Items | 301.22 | 120.09 | 289.99 | 304.2 | 350.12 |
Impairment of Goodwill | - | -13.36 | - | - | - |
Gain (Loss) on Sale of Investments | - | 9.43 | 9.61 | 9.49 | - |
Gain (Loss) on Sale of Assets | - | 0.04 | 0 | 0.03 | 0.01 |
Other Unusual Items | - | 15.39 | 6.3 | 23.16 | 17.24 |
Pretax Income | 301.22 | 131.6 | 305.91 | 336.88 | 367.38 |
Income Tax Expense | 29.1 | 6.94 | 28.09 | 29.16 | 45.02 |
Earnings From Continuing Operations | 272.12 | 124.66 | 277.82 | 307.72 | 322.36 |
Minority Interest in Earnings | - | 0.33 | 0.01 | - | - |
Net Income | 272.12 | 124.99 | 277.82 | 307.72 | 322.36 |
Net Income to Common | 272.12 | 124.99 | 277.82 | 307.72 | 322.36 |
Net Income Growth | 117.72% | -55.01% | -9.71% | -4.54% | 13.76% |
Shares Outstanding (Basic) | 383 | 379 | 386 | 385 | 347 |
Shares Outstanding (Diluted) | 383 | 379 | 386 | 385 | 347 |
Shares Change (YoY) | 1.19% | -1.84% | 0.32% | 10.97% | 0.30% |
EPS (Basic) | 0.71 | 0.33 | 0.72 | 0.80 | 0.93 |
EPS (Diluted) | 0.71 | 0.33 | 0.72 | 0.80 | 0.93 |
EPS Growth | 115.15% | -54.17% | -10.00% | -13.98% | 13.41% |
Free Cash Flow | - | -51.07 | 478.47 | 16.1 | -34.62 |
Free Cash Flow Per Share | - | -0.14 | 1.24 | 0.04 | -0.10 |
Dividend Per Share | - | 0.132 | 0.362 | 0.313 | 0.130 |
Dividend Growth | - | -63.54% | 15.65% | 140.77% | - |
Gross Margin | 100.00% | 64.09% | 70.76% | 74.91% | 76.17% |
Operating Margin | 28.91% | 11.41% | 21.62% | 23.41% | 31.08% |
Profit Margin | 26.07% | 15.51% | 22.99% | 25.61% | 29.09% |
Free Cash Flow Margin | - | -6.34% | 39.59% | 1.34% | -3.12% |
EBITDA | 338.17 | 128.37 | 294.55 | 309.48 | 360.99 |
EBITDA Margin | 32.40% | 15.93% | 24.37% | 25.75% | 32.58% |
D&A For EBITDA | 36.41 | 36.41 | 33.25 | 28.13 | 16.55 |
EBIT | 301.75 | 91.96 | 261.3 | 281.35 | 344.44 |
EBIT Margin | 28.91% | 11.41% | 21.62% | 23.41% | 31.08% |
Effective Tax Rate | 9.66% | 5.27% | 9.18% | 8.66% | 12.25% |
Revenue as Reported | - | 805.86 | 1,209 | 1,202 | 1,108 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.